Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms AETHERA
  • Sponsors Seagen; Seattle Genetics; Takeda

Most Recent Events

  • 13 Dec 2022 Results assessing the effect of the cumulative maintenance brentuximab vedotin dose on 2-year progression free survival in patients with high-risk relapsed/refractory classical Hodgkin lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 03 Dec 2021 Data was used from this trial and an observational study using a French National Hospital database to assess public health impact by combining clinical trial and real-world data RWD presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 04 Jul 2020 This trial is completed in Hungary (Global End Date: 07 May 2020), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top